Combining radionuclide therapy with a PARP inhibitor slows neuroendocrine tumour growth

Cancer of the neuroendocrine system is a moving target with managed treatment aimed at palliative care rather than a cure. Patients with neuroendocrine tumours may experience fewer symptoms and survive longer by undergoing peptide-receptor radionuclide therapy combined with a drug that makes tumour cells more sensitive to radiotherapy, say researchers presenting at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.